ID   KC1G3_HUMAN             Reviewed;         447 AA.
AC   Q9Y6M4; A8K040; B4DSH2; B7Z9Q4; E7EVD0; Q86WZ7; Q9Y6M3;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2004, sequence version 2.
DT   15-MAR-2017, entry version 164.
DE   RecName: Full=Casein kinase I isoform gamma-3;
DE            Short=CKI-gamma 3;
DE            EC=2.7.11.1;
GN   Name=CSNK1G3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Testis;
RX   PubMed=9925945;
RA   Kusuda J., Hirai M., Toyoda A., Tanuma R., Hashimoto K.;
RT   "Cloning and chromosome mapping of the human casein kinase I gamma3
RT   gene (CSNK1G3).";
RL   Cytogenet. Cell Genet. 83:101-103(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4; 5 AND 6).
RC   TISSUE=Astrocyte, Brain, and Embryonic brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-413, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-366 (ISOFORM 3),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-367 (ISOFORM 4),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-291 (ISOFORM 5),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-254 (ISOFORM 6), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 35-362 IN COMPLEX WITH
RP   INHIBITORS.
RA   Bunkoczi G., Salah E., Rellos P., Das S., Fedorov O., Savitsky P.,
RA   Gileadi O., Sundstrom M., Edwards A., Arrowsmith C., Ugochukwu E.,
RA   Weigelt J., Von Delft F., Knapp S.;
RT   "Structure of casein kinase 1 gamma 3.";
RL   Submitted (MAR-2006) to the PDB data bank.
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.30 ANGSTROMS) OF 35-362 IN COMPLEX WITH
RP   INHIBITORS.
RA   Bunkoczi G., Salah E., Rellos P., Das S., Fedorov O., Savitsky P.,
RA   Debreczeni J.E., Gileadi O., Sundstrom M., Edwards A., Arrowsmith C.,
RA   Weigelt J., Von Delft F., Knapp S.;
RT   "Inhibitor binding by casein kinases.";
RL   Submitted (FEB-2009) to the PDB data bank.
CC   -!- FUNCTION: Serine/threonine-protein kinase. Casein kinases are
CC       operationally defined by their preferential utilization of acidic
CC       proteins such as caseins as substrates. It can phosphorylate a
CC       large number of proteins. Participates in Wnt signaling. Regulates
CC       fast synaptic transmission mediated by glutamate (By similarity).
CC       {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Inhibited by triazolodiamine 1, 5-amino-3-{[4-
CC       (aminosulfonyl)phenyl]amino}-N-(2,6-difluorophenyl)-1H-1,2,4-
CC       triazole-1-carbothioamide, (S)-propane-1,2-diol, 2-({6-[(3-
CC       chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-
CC       methylbutan-1-ol, N2-[(1R,2S)-2-aminocyclohexyl]-N6-(3-
CC       chlorophenyl)-9-ethyl-9H-purine-2,6-diamine and [4-amino-2-(3-
CC       chloroanilino)-1,3-thiazol-5-yl](4-fluorophenyl)methanone.
CC   -!- SUBUNIT: Monomer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=3;
CC         IsoId=Q9Y6M4-1; Sequence=Displayed;
CC       Name=2; Synonyms=3L, CSNK1G3L;
CC         IsoId=Q9Y6M4-2; Sequence=VSP_004749;
CC       Name=3;
CC         IsoId=Q9Y6M4-3; Sequence=VSP_010256, VSP_004749;
CC         Note=Contains a phosphoserine at position 366.
CC         {ECO:0000244|PubMed:20068231};
CC       Name=4;
CC         IsoId=Q9Y6M4-4; Sequence=VSP_047055, VSP_010256, VSP_004749;
CC         Note=Contains a phosphoserine at position 367.
CC         {ECO:0000244|PubMed:20068231};
CC       Name=5;
CC         IsoId=Q9Y6M4-5; Sequence=VSP_047054, VSP_010256, VSP_004749;
CC         Note=Contains a phosphoserine at position 291.
CC         {ECO:0000244|PubMed:20068231};
CC       Name=6;
CC         IsoId=Q9Y6M4-6; Sequence=VSP_047053, VSP_047055, VSP_010256,
CC                                  VSP_004749;
CC         Note=Contains a phosphoserine at position 254.
CC         {ECO:0000244|PubMed:20068231};
CC   -!- PTM: Autophosphorylated. {ECO:0000250}.
CC   -!- MISCELLANEOUS: Triazolodiamine 1 is a commercial name for 5-amino-
CC       3-([4-(aminosulfonyl)phenyl]amino)-N-(2,6-difluorophenyl)-1H-
CC       1,2,4-triazole-1-carbothioamide.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CK1 Ser/Thr
CC       protein kinase family. Casein kinase I subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF049089; AAD26525.1; -; mRNA.
DR   EMBL; AF049090; AAD26526.1; -; mRNA.
DR   EMBL; AK289405; BAF82094.1; -; mRNA.
DR   EMBL; AK299739; BAG61634.1; -; mRNA.
DR   EMBL; AK316019; BAH14390.1; -; mRNA.
DR   EMBL; AC008541; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC026422; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471086; EAW48872.1; -; Genomic_DNA.
DR   EMBL; BC047567; AAH47567.1; -; mRNA.
DR   CCDS; CCDS34218.1; -. [Q9Y6M4-3]
DR   CCDS; CCDS4135.1; -. [Q9Y6M4-1]
DR   CCDS; CCDS43355.1; -. [Q9Y6M4-2]
DR   CCDS; CCDS59491.1; -. [Q9Y6M4-4]
DR   CCDS; CCDS59492.1; -. [Q9Y6M4-5]
DR   CCDS; CCDS59493.1; -. [Q9Y6M4-6]
DR   RefSeq; NP_001026982.1; NM_001031812.3. [Q9Y6M4-3]
DR   RefSeq; NP_001038188.1; NM_001044723.2. [Q9Y6M4-2]
DR   RefSeq; NP_001257501.1; NM_001270572.1. [Q9Y6M4-4]
DR   RefSeq; NP_001257502.1; NM_001270573.1. [Q9Y6M4-5]
DR   RefSeq; NP_001257503.1; NM_001270574.1. [Q9Y6M4-6]
DR   RefSeq; NP_004375.2; NM_004384.4. [Q9Y6M4-1]
DR   RefSeq; XP_005271949.1; XM_005271892.2. [Q9Y6M4-2]
DR   RefSeq; XP_005271951.1; XM_005271894.2. [Q9Y6M4-1]
DR   RefSeq; XP_005271952.1; XM_005271895.2. [Q9Y6M4-4]
DR   RefSeq; XP_016864558.1; XM_017009069.1. [Q9Y6M4-4]
DR   UniGene; Hs.129206; -.
DR   UniGene; Hs.741716; -.
DR   PDB; 2CHL; X-ray; 1.95 A; A=35-362.
DR   PDB; 2IZR; X-ray; 1.30 A; A=35-362.
DR   PDB; 2IZS; X-ray; 1.95 A; A=35-362.
DR   PDB; 2IZT; X-ray; 2.00 A; A=35-362.
DR   PDB; 2IZU; X-ray; 1.85 A; A=35-362.
DR   PDB; 4G16; X-ray; 2.30 A; A=34-362.
DR   PDB; 4G17; X-ray; 2.10 A; A=34-362.
DR   PDB; 4HGL; X-ray; 2.40 A; A=34-362.
DR   PDB; 4HGS; X-ray; 2.40 A; A=34-362.
DR   PDBsum; 2CHL; -.
DR   PDBsum; 2IZR; -.
DR   PDBsum; 2IZS; -.
DR   PDBsum; 2IZT; -.
DR   PDBsum; 2IZU; -.
DR   PDBsum; 4G16; -.
DR   PDBsum; 4G17; -.
DR   PDBsum; 4HGL; -.
DR   PDBsum; 4HGS; -.
DR   ProteinModelPortal; Q9Y6M4; -.
DR   SMR; Q9Y6M4; -.
DR   BioGrid; 107840; 36.
DR   IntAct; Q9Y6M4; 9.
DR   STRING; 9606.ENSP00000353904; -.
DR   BindingDB; Q9Y6M4; -.
DR   ChEMBL; CHEMBL5084; -.
DR   DrugBank; DB04751; Purvalanol A.
DR   GuidetoPHARMACOLOGY; 2001; -.
DR   iPTMnet; Q9Y6M4; -.
DR   PhosphoSitePlus; Q9Y6M4; -.
DR   SwissPalm; Q9Y6M4; -.
DR   DMDM; 47117932; -.
DR   EPD; Q9Y6M4; -.
DR   PaxDb; Q9Y6M4; -.
DR   PeptideAtlas; Q9Y6M4; -.
DR   PRIDE; Q9Y6M4; -.
DR   DNASU; 1456; -.
DR   Ensembl; ENST00000345990; ENSP00000334735; ENSG00000151292. [Q9Y6M4-3]
DR   Ensembl; ENST00000360683; ENSP00000353904; ENSG00000151292. [Q9Y6M4-2]
DR   Ensembl; ENST00000361991; ENSP00000354942; ENSG00000151292. [Q9Y6M4-1]
DR   Ensembl; ENST00000510842; ENSP00000423838; ENSG00000151292. [Q9Y6M4-4]
DR   Ensembl; ENST00000511130; ENSP00000421385; ENSG00000151292. [Q9Y6M4-6]
DR   Ensembl; ENST00000512718; ENSP00000421998; ENSG00000151292. [Q9Y6M4-5]
DR   Ensembl; ENST00000521364; ENSP00000429412; ENSG00000151292. [Q9Y6M4-3]
DR   GeneID; 1456; -.
DR   KEGG; hsa:1456; -.
DR   UCSC; uc003ktn.5; human. [Q9Y6M4-1]
DR   CTD; 1456; -.
DR   DisGeNET; 1456; -.
DR   GeneCards; CSNK1G3; -.
DR   HGNC; HGNC:2456; CSNK1G3.
DR   HPA; HPA027010; -.
DR   MIM; 604253; gene.
DR   neXtProt; NX_Q9Y6M4; -.
DR   OpenTargets; ENSG00000151292; -.
DR   PharmGKB; PA26956; -.
DR   eggNOG; KOG1165; Eukaryota.
DR   eggNOG; ENOG410XNXP; LUCA.
DR   GeneTree; ENSGT00760000119040; -.
DR   HOGENOM; HOG000182054; -.
DR   HOVERGEN; HBG000176; -.
DR   InParanoid; Q9Y6M4; -.
DR   KO; K08958; -.
DR   OMA; NREAHPH; -.
DR   OrthoDB; EOG091G0F3Z; -.
DR   PhylomeDB; Q9Y6M4; -.
DR   TreeFam; TF313349; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   SignaLink; Q9Y6M4; -.
DR   ChiTaRS; CSNK1G3; human.
DR   EvolutionaryTrace; Q9Y6M4; -.
DR   GenomeRNAi; 1456; -.
DR   PRO; PR:Q9Y6M4; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000151292; -.
DR   CleanEx; HS_CSNK1G3; -.
DR   ExpressionAtlas; Q9Y6M4; baseline and differential.
DR   Genevisible; Q9Y6M4; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0006897; P:endocytosis; IBA:GO_Central.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0008360; P:regulation of cell shape; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0016055; P:Wnt signaling pathway; IBA:GO_Central.
DR   InterPro; IPR022247; Casein_kinase-1_gamma_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF12605; CK1gamma_C; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; Kinase; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Wnt signaling pathway.
FT   CHAIN         1    447       Casein kinase I isoform gamma-3.
FT                                /FTId=PRO_0000192846.
FT   DOMAIN       43    313       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      49     57       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      117    125       Inhibitors binding.
FT   ACT_SITE    162    162       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      72     72       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES     413    413       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   VAR_SEQ       1    113       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_047053.
FT   VAR_SEQ       1     75       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_047054.
FT   VAR_SEQ     282    282       E -> EE (in isoform 4 and isoform 6).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_047055.
FT   VAR_SEQ     363    394       Missing (in isoform 3, isoform 4, isoform
FT                                5 and isoform 6).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_010256.
FT   VAR_SEQ     430    430       K -> NCQKVLNMW (in isoform 2, isoform 3,
FT                                isoform 4, isoform 5 and isoform 6).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9925945}.
FT                                /FTId=VSP_004749.
FT   CONFLICT     91     91       K -> E (in Ref. 5; AAH47567).
FT                                {ECO:0000305}.
FT   CONFLICT    174    174       G -> R (in Ref. 1; AAD26525/AAD26526).
FT                                {ECO:0000305}.
FT   CONFLICT    241    241       Y -> C (in Ref. 2; BAH14390).
FT                                {ECO:0000305}.
FT   CONFLICT    302    302       D -> E (in Ref. 1; AAD26525/AAD26526).
FT                                {ECO:0000305}.
FT   TURN         40     42       {ECO:0000244|PDB:2IZR}.
FT   STRAND       43     48       {ECO:0000244|PDB:2IZR}.
FT   STRAND       50     52       {ECO:0000244|PDB:2IZS}.
FT   STRAND       56     62       {ECO:0000244|PDB:2IZR}.
FT   TURN         63     66       {ECO:0000244|PDB:2IZR}.
FT   STRAND       67     75       {ECO:0000244|PDB:2IZR}.
FT   HELIX        83     93       {ECO:0000244|PDB:2IZR}.
FT   STRAND      102    108       {ECO:0000244|PDB:2IZR}.
FT   STRAND      111    117       {ECO:0000244|PDB:2IZR}.
FT   HELIX       123    129       {ECO:0000244|PDB:2IZR}.
FT   TURN        130    132       {ECO:0000244|PDB:2IZR}.
FT   HELIX       136    155       {ECO:0000244|PDB:2IZR}.
FT   HELIX       165    167       {ECO:0000244|PDB:2IZR}.
FT   STRAND      168    170       {ECO:0000244|PDB:2IZR}.
FT   HELIX       173    175       {ECO:0000244|PDB:2IZR}.
FT   TURN        176    179       {ECO:0000244|PDB:2IZU}.
FT   STRAND      180    183       {ECO:0000244|PDB:2IZR}.
FT   STRAND      190    193       {ECO:0000244|PDB:2IZR}.
FT   TURN        195    197       {ECO:0000244|PDB:2IZR}.
FT   STRAND      198    200       {ECO:0000244|PDB:2IZU}.
FT   TURN        213    215       {ECO:0000244|PDB:2IZR}.
FT   HELIX       218    221       {ECO:0000244|PDB:2IZR}.
FT   HELIX       228    244       {ECO:0000244|PDB:2IZR}.
FT   TURN        248    251       {ECO:0000244|PDB:2IZR}.
FT   HELIX       257    270       {ECO:0000244|PDB:2IZR}.
FT   HELIX       273    276       {ECO:0000244|PDB:2IZR}.
FT   TURN        277    279       {ECO:0000244|PDB:2IZR}.
FT   HELIX       281    292       {ECO:0000244|PDB:2IZR}.
FT   HELIX       301    314       {ECO:0000244|PDB:2IZR}.
FT   TURN        324    327       {ECO:0000244|PDB:2IZR}.
SQ   SEQUENCE   447 AA;  51389 MW;  6FAEDD605579ED3A CRC64;
     MENKKKDKDK SDDRMARPSG RSGHNTRGTG SSSSGVLMVG PNFRVGKKIG CGNFGELRLG
     KNLYTNEYVA IKLEPMKSRA PQLHLEYRFY KQLGSGDGIP QVYYFGPCGK YNAMVLELLG
     PSLEDLFDLC DRTFSLKTVL MIAIQLISRM EYVHSKNLIY RDVKPENFLI GRPGNKTQQV
     IHIIDFGLAK EYIDPETKKH IPYREHKSLT GTARYMSINT HLGKEQSRRD DLEALGHMFM
     YFLRGSLPWQ GLKADTLKER YQKIGDTKRA TPIEVLCENF PEMATYLRYV RRLDFFEKPD
     YDYLRKLFTD LFDRKGYMFD YEYDWIGKQL PTPVGAVQQD PALSSNREAH QHRDKMQQSK
     NQSADHRAAW DSQQANPHHL RAHLAADRHG GSVQVVSSTN GELNTDDPTA GRSNAPITAP
     TEVEVMDETK CCCFFKRRKR KTIQRHK
//
